Neuropathic (original) (raw)
Latest News for: neuropathic
Peripheral Neuropathic Pain Market Positioned for Significant Commercial Growth by 2034 – DelveInsight | Grünenthal ...
GetNews 16 Jun 2026
The Peripheral Neuropathic Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period ... Get a Free sample for the Peripheral Neuropathic Pain Market Report. ... Peripheral Neuropathic Pain Overview.
Peer-reviewed Publication Shows that Lateral Pharma's SCP Drugs for Neuropathic Pain Act Via the Novel Target LanCL1
PR Newswire 12 Jun 2026
a therapeutic target for neuropathic pain," shows that LAT8881, Lateral Pharma's first-generation SCP peptide, acts via LanCL1 and offers new insights into the biology underlying neuropathic pain ... a therapeutic target for neuropathic pain.
Diabetic Neuropathic Pain Market is Projected to Grow Significantly by 2034 Owing to the Launch ...
GetNews 05 Jun 2026
Key Takeaways from the Diabetic Neuropathic Pain Market. The market size for Diabetic Neuropathic Pain in the 7MM is expected to increase significantly during the forecast period from 2020–2034 ... Diabetic Neuropathic Pain Competitive Landscape.
AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain
Pharmiweb 19 May 2026
This includes pain indications such as osteoarthritis and chemotherapy-induced neuropathic pain, areas with significant unmet medical needs ... ACD137 with a focus on osteoarthritis and neuropathic pain.
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain
The Eagle-Tribune 18 May 2026
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package ... .
Dogwood Therapeutics Announces Commencement of Halneuron� Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
Nasdaq Globe Newswire 18 May 2026
New study to assess Halneuron� pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package ... .
Liavium®-CA1 (pregabalin chewable tablets) Receives FDA Conditional Approval, Redefining Canine Neuropathic Pain Care
PR Newswire 18 May 2026
PENSACOLA, Fla., May 18, 2026 /PRNewswire/ -- Pegasus Laboratories, Inc ... "Liavium-CA1 signals a turning point in canine pain management by providing veterinarians a first-of-its-kind option to effectively manage neuropathic pain," said Dr ... 21% ... .
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
ACCESSWIRE 14 May 2026
CIPN is characterized by neuropathic pain, numbness, tingling, and sensory dysfunction that may persist long after chemotherapy treatment ends ... In validated preclinical models of neuropathic pain, ...
International Neuropathic Pain consortium awarded €1.4m grant (King's College London)
Public Technologies 24 Mar 2026
Neuropathic pain is caused by nerve damage due to, for example, diabetes or cancer treatment ... Unfortunately, painkillers do not work for neuropathic pain for most people ... people with neuropathic pain.
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain (Form 6-K) (OKYO Pharma Ltd)
Public Technologies 18 Mar 2026
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain ... About Neuropathic Corneal Pain (NCP).
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain (OKYO Pharma Ltd)
Public Technologies 18 Mar 2026
) OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain ... About Neuropathic Corneal Pain (NCP).